The Cambridge biotech that doesn't block cancer's receptors - it deletes them.
For four decades, the standard way to drug a cancer protein has been to jam it - slide a small molecule into the receptor's active site and hold it shut. It works, until the tumor changes the lock. Resistance and recurrence are the two words that end most oncology success stories.
Pinetree Therapeutics, founded in 2019 and based in Cambridge's West Cambridge Scientific Park, is built around a different verb. Instead of inhibiting a cancer receptor, it degrades it - engineering antibodies that grab the target, drag it into the cell's own recycling machinery, and let the lysosome dismantle it entirely. No receptor, no signal, no easy path back for the tumor.
The company is a leader in what the field calls targeted protein degradation, or TPD. What sets Pinetree apart is where it points that idea: at membrane-bound and extracellular proteins on the cell surface - real estate that the first wave of degraders, built from small molecules for proteins inside the cell, largely couldn't reach.
Pinetree's AbReptor platform builds modular bispecific and multispecific antibodies. One arm latches onto a disease-driving receptor; the machinery co-engages the cell's endocytic system. From there, biology does the demolition in five steps.
A bispecific antibody binds the target receptor and an internalizing partner at the cell surface.
Binding triggers the start of endocytosis - the cell's uptake process.
The receptor is pulled from the membrane into the cell interior.
The cargo is routed into an endolysosomal compartment.
The lysosome breaks the receptor down - eliminating it, not just blocking it.
Because the mechanism removes the whole protein, it can reach receptor tyrosine kinases (RTKs) that are refractory to existing tyrosine kinase inhibitors and immune-checkpoint therapies - the exact targets where conventional drugs run out of road.
A best-in-class, modular antibody platform that creates bispecific and multispecific protein degraders for membrane-bound and extracellular proteins. Demonstrated preclinical efficacy and safety degrading drug-resistant RTKs that drive tumor growth.
Tumor Associated Essential Receptor Targeting AntiBody - an antibody-based platform that degrades drug-resistant or hard-to-treat receptors found across many tumor types and on immune and disease cells.
Pinetree's lead preclinical oncology candidate, degrading EGFR. Exclusively optioned globally by AstraZeneca in July 2024 and advancing toward Phase I clinical studies.
An emerging class combining AbReptor-driven degradation with antibody-drug conjugate payload delivery - degradation and cytotoxic delivery in one molecule.
As a preclinical B2B biotech, Pinetree's direct partners are pharma companies licensing its platform - most visibly AstraZeneca - and the investors funding its programs. The ultimate beneficiaries are patients with drug-resistant tumors: NSCLC, pancreatic and breast cancers among them.
Platform-based drug discovery. Revenue comes from venture financing, out-licensing, and milestone-and-royalty pharma deals rather than product sales - the classic structure of a preclinical biotech turning a platform into partnered assets.
Alongside TPD players like Arvinas, Kymera, C4 and Nurix, and extracellular-degradation peers such as Lycia. Pinetree's edge is antibody-based degradation aimed squarely at cell-surface receptors that small-molecule degraders and TKIs struggle to touch.
Song founded Pinetree in 2019 and has steered its strategy of proving one platform across many targets - a discipline that helped attract both a pharma partner and a syndicate of investors across three financing rounds. He champions AbReptor's potential to spawn a novel class of degrading antibody-drug conjugates.
Song's approach is a lesson in sequencing: rather than betting the company on a single molecule, Pinetree validated AbReptor on target after target. That repeatability is what turns a preclinical platform into a partnered pipeline - and what a big pharma buyer looks for before committing nine-figure milestones.
Each raise expanded the platform rather than chasing a single asset. The Series B was oversubscribed in a difficult biotech market - and drew both existing backers and new institutional names.
Series B investors: DSC Investment, WIDWIN Investment, STIC Ventures, Samho Green Investment, Atinum Investment, S&S Investment, SJ Investment Partners, Smilegate Investment, Gauss Capital Management, plus new investors Korea Investment Partners and SV Investment.
Ho-Juhn Song, Ph.D., launches the company in Cambridge to pursue antibody-based targeted protein degradation.
Capital to develop the platform technology for unmet medical needs.
Closes Series A and signs a global EGFR-degrader option with AstraZeneca worth $500M+ in potential milestones.
Raises Series B to push lead oncology programs toward Phase I and expand the AbReptor platform.
It develops antibody-based targeted protein degraders for cancer, using its AbReptor and TAER-TAB platforms to eliminate disease-driving membrane-bound and extracellular proteins rather than just blocking them.
Traditional tyrosine kinase inhibitors block a receptor's activity; Pinetree's degraders drag the entire receptor into the cell's lysosome to be destroyed, aiming to overcome the drug resistance that eventually defeats inhibitors.
Roughly $111M in total, including a $23.5M Series A1 (2022), a $17M Series A (2024), and a $47M oversubscribed Series B (October 2025).
In July 2024, AstraZeneca took an exclusive global license option on Pinetree's preclinical EGFR degrader candidate - a deal valued at over $500M in potential milestones and royalties.
Not yet. The company is preclinical, and its Series B is intended to push lead oncology programs toward Phase I clinical studies.